CBP/p300-IN-8
CBP/p300-IN-8 is a potent inhibitor of the CBP/P300 family of bromodomains. CBP/p300-IN-8 inhibits CBP (IC50=0.01-0.1 µΜ) and BRD4 (IC50=1-1000 µΜ) activity[1].
Product Specifications
CAS Number
2304416-91-7
UNSPSC
12352005
Target
Epigenetic Reader Domain
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cbp-p300-bromodomain-inhibitor-3.html
Purity
99.94
Solubility
DMSO : 200 mg/mL (ultrasonic)
Smiles
O=C(N1[C@@H](C)CCC2=C1C=CC3=C2N=C(CC4=CC=CC=C4)N3[C@@H]5C[C@@H](C(O)=O)CCC5)OC
Molecular Formula
C27H31N3O4
Molecular Weight
461.55
References & Citations
[1]Shawn E.R. Schiller, et al. Tetrahydro-imidazo quinoline compositions as cbp/p300 inhibitors. WO2019055877A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
BRD4
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC940204-100 1x 100 µL
Complement C4d (C4D204), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC940002-500 1x 500 µL
CD66 (CEA) (COL-1), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC041497-100 1x 100 µL
CD20 / MS4A1 (B-Cell Marker) (IGEL/1497R), CF405S conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC400155-100 1x 100 µL
CD19 (CVID3/155), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC432746-500 1x 500 µL
PD-L1 / PDCD1LG1 / CD274 / B7-H1 (Cancer Immunotherapy Target) (PDL1/2746), CF543 conjugate, 0.1mg/mL
Sign In for Pricing
View Details